Featured Article
A study by researchers at Mass General Brigham has revealed that patient adverse events are prevalent and persistent in outpatient settings.
Precision Oncology Today
Magazine
Beginning a New Era of Precision Alzheimer’s Therapeutics
Alzheimer’s is a disease associated with aging and impacts almost seven million people in the U.S. over the age of 65, with women and Black or Hispanic populations disproportionately affected by the condition. Finding an effective treatment for Alzheimer’s disease has proved to be a long and difficult quest.
5 Startups With Proteomics Potential Attracting Investor Cash
Investor appetite is growing for startups that can make proteomics faster, cheaper, and more informative for use in precision medicine. Here are five proteomics...
Trending on Inside Precision Medicine
Verve Starts Second Human Cardiovascular Gene Therapy Trial
Verve Therapeutics starts Phase I trial of its second base editing candidate therapy designed to target the PCSK9 gene.
Crick Institute and Broken String Partner for ALS Cell and Gene Therapy
The Francis Crick Institute is partnering to develop novel applications for Broken String’s proprietary DNA break-mapping platform, INDUCE-seq, to investigate the impact of genomic instability in amyotrophic lateral sclerosis (ALS).
Patient Adverse Events Prevalent in Outpatient Settings
A study by researchers at Mass General Brigham has revealed that patient adverse events are prevalent and persistent in outpatient settings.
